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RhoGEFs are central controllers of small G-proteins in cells and
are regulated by several mechanisms. There are at least 22 human
RhoGEFs that contain SH3domains, raising the possibility that, like
several other enzymes, SH3 domains control the enzymatic activity
of guanine nucleotide exchange factor (GEF) domains through
intra- and/or intermolecular interactions. The structure of the
N-terminal SH3 domain of Kalirin was solved using NMR spectros-
copy, and it folds much like other SH3 domains. However, NMR
chemical shift mapping experiments showed that this Kalirin SH3
domain is unique, containing novel cooperative binding site(s) for
intramolecular PXXP ligands. Intramolecular Kalirin SH3 domain/
ligand interactions, as well as binding of the Kalirin SH3 domain to
the adaptor protein Crk, inhibit the GEF activity of Kalirin. This
study establishes a novel molecular mechanism whereby intramo-
lecular and intermolecular Kalirin SH3 domain/ligand interactions
modulateGEFactivity, a regulatorymechanism that is likely usedby
other RhoGEF family members.
There are69 RhoGEFs in the human genome that are expected to
catalyze nucleotide exchange on 22 Rho GTPases (1). As the major
activators of the Rho GTPases, guanine nucleotide exchange factor
(GEF)2 proteins play important roles in cell signaling, rearrangement of
the cytoskeleton, membrane trafficking, and translational regulation
(2). The widespread effects of GEF domains dictate the need for tight
regulation of activity, which is underscored by the observation that
deregulation of RhoGEFs is associated with cellular transformation and
mental retardation (1, 3).
Most RhoGEFs are composed of tandem Dbl homology (DH) and
pleckstrin homology (PH) domains. RhoGEFs are regulated by cellular
localization, interaction of phosphoinositideswith the PHdomain, tyro-
sine phosphorylation, oligomerization, and other protein/protein inter-
actions (2, 4–8). Although the interaction of phosphoinositides with
the PH domain seems to be a general mechanism for modulating GEF
activity (5, 6, 9–12), other regulatory mechanisms affect a subset of
RhoGEFs. RhoGEFs often contain several domains that are involved in
their localization, associationwith other proteins, and regulation ofGEF
activity.
Approximately one-third (22) of the human RhoGEFs contain Src
homology 3 (SH3) domains (see Fig. 1). The GEFs with SH3 domains
can be grouped into three classes based on the number and arrangement
of the domains: Group I, with SH3 domains located N-terminally to the
DHand PHdomains; Group II, with SH3 domains locatedC-terminally;
and Group III, with multiple SH3 domains. Several pieces of data sup-
port the hypothesis that the SH3 domains regulate GEF activity. For
example, the cellular transforming activity of Ost is inhibited by its SH3
domain (13), and the first SH3 domain of Trio is necessary for GEF-
mediated effects on neurite outgrowth (14).
Regulation of RhoGEFs by SH3 domains could be through an inhibitory
intramolecular SH3domain/ligand association.Most SH3domains bind to
a consensus core Pro-X-X-Pro (PXXP) sequence, with higher affinity
derived from additional specificity determinants (15, 16). Intramolecular
SH3 domain/PXXP interactions regulate several proteins, including Src,
Hck, c-Abl, and Tec family tyrosine kinases (8, 17–26). Mixed-lineage
kinases are Ser/Thr kinases regulated by an intramolecular SH3 domain
interaction (26). p46phox heterodimerizes with and activates NADPH
oxidase after an intramolecular SH3 domain/ligand interaction is dis-
rupted (27, 28). p47phox also utilizes intramolecular interactions
between its SH3 domains and adjoining linker regions that are autoin-
hibitory (29). Similarly, an intramolecular interaction between the SH3
and guanylate kinase domains of PSD-95 is disrupted when its SH3
domain binds to a PXXP sequence in the protein-tyrosine kinase Pyk2
(30, 31). Clearly, intramolecular SH3 domain/ligand interactions play in
important role in the regulation of many proteins, but this has not yet
been observed in RhoGEFs.
Eight of the 22 RhoGEFs containing SH3 domains (PIX, GEF6,
PIX, Q8IVY3, Q9Y2L3, intersectin-1, Trio, and Kalirin) (Fig. 1) also
contain at least one consensus PXXP SH3 domain ligand-binding
sequence between their GEF and SH3 domains. GEFs with SH3
domains preceding or following the DH-PH domains may be regulated
by intramolecular SH3 domain/PXXP interactions.
In this study, we examined the ability of intramolecular SH3 domain/
PXXP interactions to contribute to the regulation of GEF activity. We
solved the solution structure of the N-terminal SH3 domain of rat Kali-
rin and found that it contains novel binding site(s) for intramolecular
PXXP sequences. Interaction of this SH3 domain with internal PXXP
motifs induces an additional intramolecular association with its neigh-
boringGEF domain, resulting in inhibition of GEF activity. An intermo-
lecular interaction of the PXXP motif and SH3 domain with the SH3
domain of the adaptor protein Crk robustly inhibits GEF activity. Thus,
the SH3 domain of Kalirin regulates GEF activity through both intra-
and intermolecular SH3 domain interactions.
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EXPERIMENTAL PROCEDURES
SH3 Domain Purification and Structure Determination—15N- and
15N/13C-labeled Kalirin SH3 domains were prepared by overproducing
the protein in bacteria as a glutathione S-transferase (GST) fusion, puri-
fying the GST fusion protein using glutathione-Sepharose, and recov-
ering the purified labeled SH3 domain proteins in the supernatant after
cleavage of the GST-SH3 domain linkage engineered to contain a Pre-
Scission protease cleavage site. The resulting protein consists of 12
N-terminal amino acids (GPLGSPGIPGST) from the pGEX-6P vector
and Leu1637–Ser1706 of the rat Kalirin (Kal) N-terminal SH3 domain
(referred to as Kal-SH3). All numbering is according to Kalirin-12a
(AF232669) except where indicated. Labeled SH3 domain proteins were
dialyzed into 50 mM HEPES (pH 6.4), 150 mM NaCl, and 1 mM dithio-
threitol and were supplemented with D2O to 7.5%. Two- and three-
dimensional spectra were recorded on Varian 500- and 600-MHz spec-
trometers at 25 °C using pulse sequences supplied by the manufacturer.
Data were processed using NMRPipe, and peaks were assigned using
XEASY (32, 33). The upper bounds for interproton distances were cal-
ibrated from the nuclear Overhauser effects using CALIBA (34). Dihe-
dral restraints were based on both TALOS and the JHNH coupling con-
stants determined in a three-dimensional HNHA experiment (35–37).
Chemical Shift Titration Experiments—For chemical shift mapping,
titration of PKTP, PLSP, PLPP, AKTP, and tPKTA (where t is trio)
peptides (0–8 mM) to 15N-labeled SH3 domain (590–685 M) was
assessed by 15N heteronuclear single quantum correlation (HSQC)
analysis. Synthesized peptides were purified by reverse-phase high pres-
sure liquid chromatography, and amino acid sequences were confirmed
by Edman degradation and mass spectrometry. The peptide sequences
for PKTP, PLSP, and PLPP are shown in Fig. 3. The sequences for AKTP
(PIQLAKTPAKLRNNSK) and tPKTA (PIHIPKTAPAATRQKGR)
each have a single Pro-to-Ala substitution in the PKTP sequence (bold-
face). Peptides were dissolved in the same buffer as the SH3 domain.
Chemical shift changes were calculated using the formula (H
0.17N)1/2 (38).
Cell Culture and Transfection—pEAK Rapid cells (an HEK-293 cell
variant; Edge BioSystems, Gaithersburg, MD) were maintained in Dul-
becco’s modified Eagle’s medium/nutrient mixture F-12 containing 200
units/ml penicillin G, 20 g/ml streptomycin sulfate, and 10% fetal
bovine serum; plated on polylysine (0.1 mg/ml)-coated dishes; and pas-
saged weekly. Transient transfections were performed using Lipo-
fectamine 2000 and Opti-MEM (Invitrogen) as described by the manu-
facturer. After a 4-h exposure to theDNA/Lipofectamine 2000mixture,
cells were incubated overnight in Dulbecco’s modified Eagle’s medium/
nutrient mixture F-12 containing 10% fetal calf serum and then for 24 h
in serum-free Dulbecco’s modified Eagle’s medium/nutrient mixture
F-12 containing insulin/transferrin/selenium (Invitrogen), penicillin/
streptomycin, and 1mg/ml bovine serum albumin (fatty acid-free) prior
to extraction or fixation.
GEF Activity Assays—GEF assays were performed following the
release of N-methylanthraniloyl-GDP (mant-GDP) from loaded GST-
Rac1 orGST-RhoGusing purified proteins as described previously (39–
41) with modifications. GST-Rac1 expressed in Escherichia coli was
purified using glutathione-Sepharose as described previously (42) and
dialyzed against assay buffer (50 mM HEPES, 100 mM NaCl, and 1 mM
dithiothreitol (pH 7.6)) supplemented with 1 mM EDTA and then again
with assay buffer lacking EDTA. His/Myc-tagged Kal5, Kal7, Kal8,
Kal8(P470A) (PLSA), Kal8(P1573A) (PKTA), Kal8(P1814A) (PLPA),
Kal8(P470A/P1573A/P1814A) (PXXP), and GEF1 proteins were puri-
fied from transfected HEK-293 cells using HisBind resin (Novagen,
Madison, WI) as described by the manufacturer. Before each assay,
GST-Rac1 or GST-RhoG (5–20 M) was loaded with mant-GDP (100
M) in a volume of 80l and supplementedwith 10mMMgCl2. In some
experiments, unbound mant-GDP was removed using a NICKTM G-50
column (GE Healthcare). Fluorescence was measured by excitation at
360 nm and emission at 460 nm and was recorded using a Wallac VIC-
TOR2 Model 1420 96-well plate reader. Reactions were initiated by
addition of GTP to 800 M and 20 l of Kalirin in reaction buffer.
Protein concentrations were determined by bicinchoninic acid assay
(Pierce) or by densitometry of Coomassie Blue-stained gels using bovine
serum albumin as a standard. In some cases, initial reaction rates (with
buffer background rates subtracted) are reported in a bar graph (n 3)
with standard deviations. Statistical analysis was performed using a
non-parametric one-way analysis of variance with a Newman-Keuls
algorithm to determine significant differences or Student’s one-tailed t
test.
Activation of Rac2 inHEK-293 cells transfectedwithKalirin plasmids
(cotransfected with pEBB-Crk1 in some experiments) was analyzed
using aGSTeffector protein binding assay kit (Upstate Biosystems, Lake
Placid, NY) (43). PCR analysis of cDNA fromHEK-293 cells showed the
presence of Rac2, but not Rac1. For Rac activation assays, cell superna-
tants prepared inMLB buffer (25 mMHEPES, 150mM sodium chloride,
1% Nonidet P-40, 10 mM magnesium chloride, 1 mM EDTA, 10% glyc-
erol, 0.3 mg/ml phenylmethylsulfonyl fluoride, 1.0 mM sodium vana-
date, and protease inhibitors (pH 7.5)) (44) were incubated with gluta-
thione-agarose beads containing immobilized Pak (p21-activated
kinase) p21 binding domain (residues 67–150; 10.0 g), and unbound
protein was removed with three washes of MLB buffer.
Far-Western SH3 Domain Array Analysis—Far-Western analysis
was performed using extracts prepared fromHEK-293 cells transfected
with pEAK10-Kal8 and an array containing 38 different GST-SH3
β
α
FIGURE 1. Schematic diagram of human RhoGEFs that contain SH3 domains. Pro-
teins are grouped according to those that have an SH3 domain N-terminal (Group I) or
C-terminal (Group II) to the RhoGEF or that havemultiple SH3 domains (Group III). Other
domains indicated are the calponin homology (CH; pink circles), kinase (green ovals),
protein kinase C conserved region C1 (black ovals), SH2 (blue ovals), C2 calcium-binding
(turquoise circles), EPS15homology (light blue circles), Ig/fibronectin type III (brownovals),
Sec14p (brown trapezoids), and adaptor (blue hexagon) domains. sGEF, SH3 domain-con-
taining GEF; nGEF, neuronal GEF.
Regulation of GEF Activity by SH3 Domains
JULY 7, 2006•VOLUME 281•NUMBER 27 JOURNAL OF BIOLOGICAL CHEMISTRY 18775
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
domain proteins (referred to as GST-SH3) spotted at two different con-
centrations (version 1.00; Panomics, Fremont, CA). The array mem-
brane was blocked with phosphate-buffered saline and 5% dehydrated
milk for 30 min, washed, and incubated with cell extracts (800 l) in 6.0
ml of phosphate-buffered saline supplemented with 0.5% Triton X-100
and 0.3 mg/ml phenylmethylsulfonyl fluoride. Arrays were washed
three times with Tris-buffered saline/Tween 20 and then analyzed by
Western blotting using anti-Myc monoclonal antibody 9E10, which
recognizes theMyc tag at the N terminus of transfected Kal8. A control
Western blot analysis showed that anti-Myc antibody recognized only
the transfected protein (data not shown).
Co-immunoprecipitation—For Kal8-Crk co-immunoprecipitation
experiments, HEK-293 cells were cotransfected with expression
constructs for Myc-Kal8 or Myc-Kal8(PKTA) and for Crk1 or
Crk1(W170K). Cell lysates (10% (w/v)) were prepared in 50mMHEPES
(pH 7.6), 150 mM NaCl, 10% glycerol, and 0.5% Triton X-100 with a
mixture of protease inhibitors (44). Insoluble material was removed by
centrifugation at 16,000 g for 30 min. Lysate (200 g) was incubated
with antiserum as indicated for 2 h with shaking and then centrifuged at
10,000 g for 10 min to remove any insoluble material. Immune com-
plexes were incubated with protein G-Sepharose (Amersham Bio-
sciences, Uppsala, Sweden) for 1 h and washed three times with buffer.
Proteins were eluted by boiling in SDS-PAGE sample buffer and ana-
lyzed by Western blotting.
GST PulldownAssay—GST pulldown experiments were used to ana-
lyze GEF1 binding to the SH3 domain, Crk binding to different frag-
ments of Kal7 and Kal8, and Kal5 binding to Crk1. Each GST-Kalirin
chimera was purified from E. coli BL21 or Rosetta (Novagen) using glu-
tathione-Sepharose or glutathione-agarose as described previously (42).
The GST fusion proteins included amino acids 517–976 for spectrin
repeats 4–7, Lys1274–Arg1575 for GEF1, Lys1274–Met1454 for the DH1
domain, Ser1453–Arg1575 for the PH1 domain, Thr1615–Val1644 for the
Kal7 C terminus (AF230644) (45), Ser1453–Ser1706 for the PH-linker-
SH3 domain, and Leu1637–Ser1706 for the SH3 domain. To assess GEF
binding toKal-SH3, theHis/Myc-taggedKalirinGEF1 domain (referred
to as Kal-GEF1) was prepared from transfected 293 cells using HisBind
affinity resin as described by the manufacturer. GST-SH3 (5 g) or this
domain preincubatedwith 0.5mMPLSP, PKTP, PLPP, or AKTP peptide
was incubatedwithKal-GEF1 inMLBbuffer for 1 hwith shaking at 4 °C.
Similar experimentswere performed using purifiedMyc-Kal5 instead of
Kal-GEF1. The affinity resin was washed three times with 500l of cold
MLB buffer. To map the Crk-binding site in Kalirin, Crk1 was prepared
as described for the GST-Kalirin chimera and incubated with thrombin
to release Crk1 from GST; Crk1 protein was recovered from the super-
natant. Individual GST-Kalirin fusion proteins (5 g) were incubated
with purified Crk1 (100 ng) in 900 l of TMT buffer (20 mMNaTES, 10
mM mannitol, and 1% Triton X-100 (pH 7.4)) for 2 h with shaking at
4 °C. Protein complexes isolated with glutathione-Sepharose or gluta-
thione-agarose were washed once with 500 l of cold TMT buffer. For
each experiment, proteins bound to the beads were eluted by boiling in
SDS-PAGE sample buffer. Samples were analyzed byWestern blot anal-
ysis, and blots were also stained with Coomassie Blue R-250.
RESULTS
Kal-SH3Has a Structure Similar to That ofOther SH3Domains—DH
proteins containing SH3 domains are a major subgroup of RhoGEFs.
We determined the structure of Kal-SH3 by NMR spectroscopy as a
basis for investigating the role of SH3 domains in regulating GEF activ-
ity. 15N- and 15N/13C-labeled SH3 domains were purified (Fig. 2A,
arrow) and used to solve the structure. Sequential assignments were
determined from HNCACB and HN(CO)CACB experiments. Assign-
ments of side chain carbons and protons were determined using
C(CO)NH and HC(CO)NH total correlated spectroscopy and HCCH
COSY experiments. Long- and short-range distance constraints were
determined from 15N-edited nuclearOverhauser effect-HSQC and 13C-
edited HSQC-nuclear Overhauser effect spectra. Torsion angle
restraints ( and ) were determined using TALOS, and  angle
restraints were validated using an HNHA experiment (37). Restraints
for 1 angles were determined from an HNHB spectrum. Hydrogen
exchange experiments were unsuccessful, so hydrogen bond restraints
were included only for internal  sheet residues that showed strong
backbone amide proton couplings. Structure calculations were per-
formed using CYANA and further refined using X-PLOR with experi-
mental distance and angle constraints as described (36, 46).
Structural statistics are shown in Fig. 2B. The structure has back-
bone and side chain root mean square (r.m.s.) deviations similar to or
better than those of other SH3 domain structures determined by
NMR (e.g. Protein Data Bank codes 1AON, 1AEY, 1ARK, 1AWW,
and 1H3H). Superposition of the backbone for an ensemble of 20
lowest energy structures is shown as a stereo image in Fig. 2C. Kal-
SH3 has a fold similar to those of other SH3 domains, with three
pairs of antiparallel  strands connected by RT-Src, n-Src, and distal
loops and a 310 helix (Fig. 2D). Alignment of the SH3 domain protein
backbone with that of the representative Sem5 C-terminal SH3 domain
(Fig. 2E) shows similar tertiary folds (r.m.s. deviation of 1.8 Å). A search
for proteinswith similar three-dimensional structures usingDALI iden-
tified several SH3 domains, with -spectrin (Protein Data Bank code
1TUD) and melanoma-derived growth regulatory protein (code 1I1J)
producing the lowest r.m.s. deviations (2.0 Å) (47). One of the most
notable differences in the Kal-SH3 structure is reorganization of the
loops. A cis-Pro peptide bond in the distal loop of Kal-SH3 (Fig. 2D, red
arrow) was assigned on the basis of strong nuclear Overhauser effects
between H and NH of Ser63 with H of Pro64. This is the first reported
cis-Pro in the distal loop of an SH3 domain. The Ser63-Pro64 sequence is
conserved in Kalirin proteins from human, mouse, rat, frog, pufferfish,
and chicken, and we anticipate that the cis-Pro peptide bond is also
conserved in these paralogs. The SH3 domain of the RhoGEF protein
Vav has a cis-Pro in its RT-Src loop that regulates intra- and intermo-
lecular SH3 domain interactions (38).
Kal-SH3Binds to Internal PXXPMotifs, Suggesting an Intramolecular
SH3 Domain/Ligand Interaction—Kal8 contains three consensus SH3
domain recognition motifs (PXXP) that might interact with SH3
domains: one in spectrin repeat 3 (PLSP), one in the linker between the
GEF and SH3 domains (PKTP), and one C-terminal to the SH3 domain
(PLPP) (Fig. 3A). To test whether the SH3 domain binds any of these
PXXP motifs, 16-residue peptides encompassing these sequences (Fig.
3A) were synthesized. HSQC chemical shift analysis was used to exam-
ine whether any of the peptides interact with Kal-SH3. The three pep-
tides bound to the SH3 domain with varying affinities.
An overlay of HSQC spectra for the SH3 domain in the absence and
presence of the PKTP peptide (at50% saturation) is shown in Fig. 3B.
The majority of PKTP-induced chemical shift movements were 0.05
ppm (15N  0.1713C), indicating that the gross conformation of the
protein did not change; however, significant reproducible shifts for sev-
eral backbone amide resonances were observed. Binding of the PKTP
peptidewas next analyzed by chemical shift titration. The inset in Fig. 3B
shows the change in chemical shift of the His30 cross-peak with increas-
ing concentrations of PKTP. A select group of resonances showed sim-
ilar dose-dependent shifts of 0.15 ppm upon addition of the PKTP
peptide (Fig. 3C ).
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Arepresentative chemical shift plot forGlu18 illustrated a cooperative
binding isotherm that was typical for each residue showing significant
chemical shift changes (Fig. 3D). All peaks approached saturation near a
1.5-fold molar ratio of the PKTP peptide to the SH3 domain, with an
average midpoint value of 410  68 M (n  17) upon fitting to a
sigmoidal curve. At SH3 domain/PKTP peptide molar ratios of1, we
observed numerous peaks that began to disappear while new peaks
began to appear, indicating a conformational change (data not shown).
Presumably, after saturation of the first binding site, a second binding
event induces a conformational change. The cooperative binding curves
observed for the chemical shift titration experiments could be explained
by the presence of two PKTP ligand-binding sites or bymultimerization
of the SH3 domain. Because the peak line widths did not change, we
favor two PXXP-binding sites. A Hill plot of the titration data for Glu18
was similar to those for other residues, yielding aHill coefficient of 2.5
0.6 (n  4), supporting cooperative binding and the hypothesis that
Kal-SH3 has two binding sites for the PKTP peptide ligand (Fig. 3E).
Of the three Kal8 PXXP motif peptides tested, the PKTP peptide
showed the highest affinity for the SH3 domain (Fig. 3F). The PKTP
peptide showed cooperative binding curves (Fig. 3D), whereas the PLSP
peptide (located in spectrin repeat 3) produced a typical non-coopera-
tive binding isotherm. Fitting the data to a standard binding isotherm
equation yielded a Kd of 552  104 M (n  5) (Fig. 3F) (48). At the
maximal PLPP peptide (located C-terminal to the N-terminal SH3
domain) concentration of 760 M, the binding isotherms did not
approach saturation, precluding calculation of aHill coefficient or bind-
ing constant. The majority of residues affected by the PLPP and PLSP
peptides were also affected by the PKTP peptide; however, PLPP and
PLSP binding each affected a largely different subset of these residues.
These chemical shift mapping experiments suggest that PLPP and PLSP
bind to different sites on the SH3 domain and that PKTP binds to both
of these sites.
The intramolecular interaction between the PKTP peptide sequence
N-terminal to the SH3 domain and the SH3 domain is ofmodest affinity
(midpoint value of 410 M). For an intermolecular protein/protein
interaction, we must consider whether this affinity is biologically rele-
vant. If we approximate the PKTP ligand concentration in an intramo-
lecular interaction by assuming that the ligand is constrained to a 19-nm
FIGURE 2. Structure of Kal-SH3. A, Coomassie
Blue-stained gel showing various steps in the pro-
duction and purification of recombinant 15N-la-
beledSH3domain. Thearrow indicatesSH3domain
protein used for structural determination. IPTG, iso-
propyl -D-thiogalactopyranoside. B, structural sta-
tistics for the calculated ensemble of SH3 domain
structures. 20 structures calculated with CYANA
were energy-minimized in X-PLOR. r.m.s. devia-
tions (RMSD) were calculated against the mean.
Ramachandran analysis was performedwith PRO-
CHECKVersion3.4.4. All statistics aremeans S.D.
NOE, nuclear Overhauser effect. C, overlay of the
ensemble of 20 SH3 domain structures for the
best fit of residues 17–76. Loops are colored blue,
and theNandC termini are indicated. Pairs of anti-
parallel sheets are coloredmagenta (1 and4),
orange (2 and 3), and pale green (5 and 6).D,
ribbon diagram of the SH3 domain with second-
ary structural elements, loops, and termini
labeled. Color and orientation are the same as
described for C. The red arrow indicates the distal
loop where the cis-Pro bond is located. E, Kal-SH3
backbone (residues 17–78; red) fit to backbone
residues for the Sem5 SH3 domain (residues 155–
211; blue; Protein Data Bank code 2SEM) using the
program MolMol. The r.m.s. deviation for peptide
backbone Kal-SH3 and Sem5 residues in second-
ary structural elements is 1.8 Å.
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FIGURE 3.Kal-SH3 binds intramolecular PXXPpeptides. A, schematic representation of Kal8 with the location and identification of PXXP peptides. Domains are as described in the
legend to Fig. 1. B, overlaid 15N-edited HSQC spectra of labeled SH3 domain without (black peaks) and with (red peaks) 330 M PKTP peptide. Trp54 side chain and His30 backbone
amide resonances are labeled. The inset is an expanded view of the area bordered by dashed lines and shows migration of the His30 backbone amide cross-peak with increasing
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diameter sphere (based on a linear extension of 47 amino acids between
the SH3 domain and the PKTPmotif), its effective concentration would
be 20 mM, far greater than the affinity of the SH3 domain for this
peptide. Given these relative affinities and concentrations, an intramo-
lecular SH3 domain/PKTP interaction should be highly favored over a
homodimeric intermolecular interaction. In this situation, we would
expect the Kal-SH3/PKTP interaction to breathe frequently, making
both the SH3 domain and its ligand available for interaction with other
SH3 domains or SH3 domain ligands. The affinity of this intramolecular
SH3 domain-PKTP complex is similar to that reported for the intramo-
lecular interaction between theTec SH3domain and its adjoining PXXP
motif (Kd  2.0 mM) (23). Even artificially juxtaposing a PXXP motif
next to an SH3 domain can generate an intramolecular SH3 domain-
PXXP motif complex (49). Furthermore, weak protein/protein interac-
tions with similar affinities have biological significance (50).
Prolines in the PKTP Peptide Are Required for Its Interaction with
Kal-SH3—To test whether the proline residues in the PKTP motif are
critical for its interaction with the SH3 domain, we examined whether
Kal-SH3 bound PKTP peptides with Pro-to-Ala mutations. The AKTP
peptide has the N-terminal proline mutated to alanine, and a peptide
corresponding to the same region in Trio has the C-terminal proline
substituted with alanine (tPKTA). These peptides induced small chem-
ical shift changes only at high concentrations. At similar concentrations,
these peptides yielded chemical shift changes that were substantially
less than those of the PKTP peptide (Fig. 3F), indicating that each of the
two prolines in the PKTP peptide is important for interaction with
Kal-SH3.
Kal-SH3 Contains a Novel Binding Site(s) for PXXP Ligands—The
cooperative binding isotherms suggest that the PKTP peptide binds to
two sites on the SH3 domain. Residues showing peptide-induced chem-
ical shift changes weremapped onto the surface of the SH3 domain (Fig.
4A, PKTP). A 180° rotation is shown for each surface map to allow
viewing of all residues affected by peptide ligands. The PKTP peptide
bound to a contiguous stretch of residues on both faces of the protein.
Because the PLSP peptide showed a typical exponential binding iso-
therm, we mapped its binding site. The residues affected defined a sub-
set of residues affected by PKTP, suggesting a single binding site for
PLSP (Fig. 4A, PLSP). The majority of residues affected by PLSP (Ala29,
Ser30, Glu33, Leu45, Glu46, Arg47, Ser49, andArg51)mapped to a cluster of
residues in the RT-Src and n-Src loops (Fig. 4A, PLSP), and nearly all
were also affected by the PKTP peptide. These residues define putative
binding site 1 (colored blue; referred to hereafter as site 1).
Titration with the PKTP peptide also showed shifts in a second clus-
ter of residues (Fig. 4A, colored green). Titration with the PLPP peptide
(Fig. 4A, PLPP, colored green) affected this same cluster of residues
(Cys17, Glu18, Leu19, Leu34, Val42, Glu43, Leu44, and Gly68) and three
additional residues in the RT-Src loop of site 1 (colored blue). This
second cluster is hereafter referred to as site 2 andmapped to the1,4,
and 6 strands.
To compare sites 1 and 2 in Kal-SH3 with the ligand-binding sites of
other SH3 domains, the Kal-SH3 sequence was aligned with sequences
of other SH3 domains with known structure and ligand-binding sites,
and the putative canonical PXXP ligand interaction site was mapped
onto the surface of Kal-SH3 (Fig. 4A,Canonical). Surprisingly, both sites
1 and 2 inKal-SH3were at a different location than the canonical ligand-
binding site observed in most other SH3 domains. Together, the
observed cooperative binding curves, a Hill coefficient of2, and map-
ping of different binding sites strongly support the presence of two
cooperative PXXP-binding sites in Kal-SH3. Although unlikely, even if
Kal-SH3 has just one PXXP motif-binding site, it is distinct from the
canonical site in most other SH3 domains and indicates a unique prop-
erty of Kal-SH3.
To gain further insight into the novel SH3 domain ligand-binding
site(s), we compared the sequences of eight Kalirin orthologs and para-
logs from several species (Fig. 4B, upper). Residues in site 1 (colored
blue) had 43% amino acid identity, whereas residues in site 2 (colored
green) were 75% conserved among the eight species examined.We com-
pared conservation of these sites in Kalirin with that in eight SH3
domains with identified PXXP-binding sites that we randomly selected
from the Protein Data Bank (Fig. 4B, middle, colored magenta). Of the
8–17 amino acids involved in binding PXXP ligands in the typical SH3
domain proteins, only one completely conserved Trp residue was iden-
tified. The level of conservation of the canonical binding site between
the Grb2 and Sem5 orthologs is similar to that observed for sites 1 and
2 between Kalirin orthologs and paralogs. These sequence comparisons
demonstrate that PXXP sites 1 and 2 are conserved in Kalirin homologs.
Moreover, the PXXP-binding site(s) in Kal-SH3 are distinct from those
in other non-canonical SH3 domain ligand-binding sites (Fig. 4B, lower,
coloredmagenta).
Intramolecular SH3 Domain/PXXP Peptide Interactions Control the
Catalytic Activity of Kal-GEF1—Intramolecular interactions of SH3
domains with PXXP motifs control the activities of tyrosine kinases,
mixed-lineage kinases, and several other proteins (8, 17–26). We
wanted to determine whether intramolecular Kal-SH3/PXXP interac-
tions regulate the exchange activity of the Kalirin N-terminal GEF
domain. Kalirin is a RhoGEF for the Rho GTPases Rac1 and RhoG (42,
45). We examined whether the intramolecular SH3 domain/PKTP
interaction modulates the activity of Kal-GEF1 toward Rac1 in fluoro-
genic GEF assays with purified fragments of Kalirin (Fig. 5A) (41). The
activity of Kal-GEF1 was not significantly affected by addition of either
Kal-SH3 or the PKTP peptide alone. However, in the presence of an
excess of bothKal-SH3 and the PKTPpeptide, GEF activity was reduced
by4-fold compared with the activity of Kal-GEF1. These results sug-
gest that an intramolecular SH3 domain-PKTP complex can inhibit
GEF activity.
We therefore investigated whether the SH3 domain/PKTP interaction
with the GEF domain functions similarly within full-length Kal8. Fluoro-
genicGEF assayswithGST-Rac purified frombacteria and full-lengthKal8
purified from transfected HEK-293 cells were used to test this model. Kal8
catalyzednucleotide exchange on 3.8MGST-Rac1with a turnover rate of
5 molecules/h, 1⁄20th the rate of GST-Rac1 exchange catalyzed by the
isolated Kalirin GEF1 domain (114 molecules/h). This difference demon-
strates the presence of potent inhibitory interactions within Kal8 (Fig. 5B).
The three Kal8 proteins mutated at each individual PXXP site were each
purified and assessed for GEF activity; the activity of each mutant Kal8
protein was similar to that of wild-type Kal8 (data not shown).
concentrations of PKTP peptide (0M (black), 110M (red), 220M (orange), 330M (green), 500M (cyan), and 750M (blue). C, titration plot showing the distance each SH3 domain
backbone amide resonancemoves as the concentration of PKTPpeptide is increased. Colors correspond to the concentration of peptide as indicated. Cys17, Glu18, Leu19, Ala29, His30,
Glu33, Leu34, Val42, Glu43, Leu45, Ser49, Arg51, Glu67, and Gly68 show chemical shift changes of 0.15 ppm (black line). D, binding isotherm for the PKTP peptide and SH3 domain
showing the dose dependence of changes in Glu18 chemical shifts. Data were fit to an equation for a sigmoidal curve (red). Normalized changes in chemical shifts are derived from
the following equation: (obs	 initial)[PXXP]/(final	 initial)[SH3]. E, Hill plot for bindingof the PKTPpeptide to the SH3domainbasedon the chemical shifts of Glu
18. F, chemical shift
titration for the response of Ala29 to the PKTP, PLSP, PLPP, AKTP, and tPKTA peptides. In B–F, [SH3 domain] 590 M, except for the titration of the PLPP peptide in F, where [SH3
domain] 685 M. For quantitation of all chemical shifts, the 15N dimension is scaled by a factor of 0.17 relative to the 1H dimension (38).
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FIGURE4.Mappingof twopotential sitesonKal-SH3 forbindingof intramolecular PXXPmotifs.A,molecular surface representations of Kal-SH3 showing residues affectedupon
interaction with various PXXP peptides. The lower surface plots represent an 180° rotation about the z axis of the upper surface plots. Residues showing chemical shifts upon
interaction with the PXXP peptide are colored as follows. Background was defined as the maximal chemical shift observed for residues in the N and C termini, which are disordered
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Because all three PXXP motifs in Kal8 bound to Kal-SH3, we gen-
erated a Kal8 protein mutated at all three sites (Kal8PXXP). When
purified and assayed using Rac1, Kal8PXXP was 1.5  0.1-fold
more active than wild-type Kal8 or Kal8 with a single PXXP motif
mutated (Fig. 5B, inset). Similar results were obtained using GST-
RhoG as a substrate (data not shown). Although intramolecular SH3
domain/ligand regulation of GEF activity was less pronounced in
wild-type Kal8 (Fig. 5B) than in isolated fragments (Fig. 5A), both
experiments provide evidence that PXXP motifs in Kalirin bind to its
SH3 domain and inhibit GEF activity. The differences in these exper-
iments (1.5-fold versus 4-fold) may be due to steric restriction of the
domains involved. In addition to the modest role of the intramolec-
ular SH3 domain/PXXP interaction in modulating the GEF activity
of Kal8, more potent regulatory mechanisms remain to be identified.
Kal-SH3/PXXP Ligand Interactions Facilitate Association with the
GEF Domain—The effect of intramolecular SH3 domain/PXXP inter-
actions on GEF activity suggests that the SH3 domain-PXXP complex
binds to the GTPase or directly to the GEF1 domain. To test whether
Kal-SH3 binds to Kal-GEF1, we performedGST pulldown experiments.
Myc-tagged Kal-GEF1 purified from transfected HEK-293 cells was
incubated with GST or GST-SH3 in the absence or presence of the
PKTP peptide, and bound Kal-GEF1 was analyzed (Fig. 5C, upper
panel). In the absence of the PKTP peptide, Kal-GEF1 did not bind to
GST-SH3. However, in the presence of the PKTP peptide (2-fold
above its midpoint Kd), significant binding of GEF1 to GST-SH3 was
observed. We next investigated whether the PLSP and PLPP peptides
affect binding of GEF1 to Kal-SH3 (Fig. 5C). Again, in the presence of
excess PLSP or PPLP peptide, Kal-GEF1 bound to GST-SH3. In the
and should not change upon ligand binding. Residues colored blue have chemical shift changes of 0.05 ppm for the PLSP peptide and 0.14 ppm for the PKTP peptide and
represent site 1. Residues colored green have chemical shift changes of 0.14 ppm for the PKTP peptide and 0.06 ppm for the PLPP peptide and represent site 2. Changes in
chemical shifts not colored in this figure are Val21 and Ser63 for the PLSP peptide and Glu67 for the PKTP peptide. The canonical PXXP-binding site mapped in other SH3 structures is
shownon the far right (coloredmagenta) B, alignment of Kalirin and TrioN-terminal SH3domains fromdifferent species (upper) with SH3domains of defined structurewith canonical
ligand-binding sites (middle) and non-canonical binding sites (lower). The frog Kalirin sequence is derived froman expressed sequence tag that ismissing theN-terminal SH3 domain
sequence (dashes). The secondary structure of Kal-SH3 is indicated above the sequences and is color-coded as described in the legend to Fig. 2. Kalirin residues that show chemical
shift changes of0.15 ppm upon binding of the PKTP peptide (330M) to the SH3 domain (590M) are colored blue for site 1 and green for site 2. Numbering is as for the structural
determination of the SH3 domain. Residues coloredmagenta are ligand-binding residues observed in the structures of Fyn (Protein Data Bank code 1AON), c-Src (code 1NLP), Abl
(code 1ABO), -spectrin (-sp; code 1HD3), Grb2 (N terminus; code 1AZE), c-Crk (N terminus; code 1CKA), Sem5 (C terminus; code 2SEM), GADS (code 1H3H), p67phox (code 1K4U),
Pex13p (code 1NM7), Grb2 (C terminus; code 1GFC), and Vav1 (code 1GCQ).
FIGURE 5. An intramolecular SH3 domain/ligand interaction regulates an interaction between the SH3 and GEF domains of Kal8. A, in vitro GEF assay following release of
fluorescentmant-GDP from loadedGST-Rac1 (19M). Reactions (100l) contained Kal-GEF1 purified from transfected 293 cells (1.1M), the PKTP peptide (0.5mM), and GST-Kal-SH3
(655M) as indicated. Thebackground rateofmant-GDP releasewas subtracted fromreportedvalues.Error bars represent S.D. values (n3). *, significantdifference fromcontrol (p
0.001). B, representative in vitro GEF assays using GST-Rac1/mant-GDP (3.8 M) as a substrate for GST-GEF1, Kal8, or Kal8PXXP (3.1 nM). The inset shows the rate of fluorescence
change/min for Kal8 and Kal8PXXP (n 6; p 0.0001)C, Myc-taggedKal-GEF1 purified from transfected 293 cells (9M) and incubatedwithGST or GST-SH3with orwithout various
peptides (0.5 mM) as indicated. The amount of Myc-tagged Kal-GEF1 boundwas assessed by a pulldown assay using glutathione-Sepharose, followed byWestern blot (WB) analysis
with anti-Myc antibody.
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presence of themutant AKTP peptide, which has vastly reduced affinity
forKal-SH3, noGEF1-SH3domain interactionwas observed, indicating
that interaction of the PXXP peptides with the SH3 domain is required
for its associationwith theGEF1 domain. These experiments establish a
novel mechanism by which the GEF activity of Kalirin is regulated.
Crk Interacts and Co-localizes with Kalirin—Because intramolecular
SH3 domain/PXXP interactions modestly regulate the GEF activity of
Kalirin, the SH3 domain and/or adjoining PKTP ligand provides an
attractive means to regulate Kalirin GEF activity by other proteins. To
test this hypothesis, we sought to identify proteins that bind the PKTP
sequence or the SH3 domain.
We performed a screen to identify proteins with SH3 domains that
bind toKal8. The array utilized contained 38 SH3 domains and controls.
Extract from HEK-293 cells expressing exogenous Myc-Kal8 was incu-
bated with the SH3 domain protein array, and bound Kal8 was detected
by Western analysis. Kal8 bound to SH3 domains from Crk, Hck, Fyb,
and -spectrin and moderately to Fgr, Yes-1, and Itk (interleukin-2-
inducible T-cell kinase); binding to control GST protein and several
other SH3 domains was not observed (Fig. 6A). A similar profile was
observed when extracts prepared from HEK-293 cells transfected with
Kal5 or Kal7 (smaller Kalirin isoforms) or purified Kal5 were used, sug-
gesting that Kalirin proteins bind directly to these SH3 domains (data
not shown). Because the Crk ortholog in C. elegans (CED-2) genetically
interacts with UNC-73 (the Kalirin paralog) in neuronal precursor cell
migration and because of the established roles of Kalirin and Crk in
axonal growth, we chose to focus on the interaction of Kalirin with Crk
(42, 51–54).
Mapping Regions Responsible for Interaction of Kalirin with Crk1—The
PKTP sequence in Kal8 is within a consensus Crk SH3 domain interac-
tion motif (PXXPXK) (see Fig. 3) (55), suggesting that the linker region
between the N-terminal GEF and SH3 fragment, which contains the
PKTPAK sequence, is responsible for the interaction between Crk and
Kalirin. To determine which regions of Kalirin interact with Crk, we
examined the binding of purified recombinant chicken Crk1 to various
GST-Kalirin fragments. As expected, Crk1 interacted with the PH-link-
er-SH3 fragment, but not with the DH1, PH1, and DH1-PH1 (GEF1)
domains or with 30 amino acids of the Kal5/Kal7 C terminus (Fig. 6B).
Quite unexpectedly, Crk1 also bound to Kal-SH3. Binding of Crk1 to
Kal-SH3 was abolished in a mutant containing scrambled residues in
the RT-Src loop (SH3RT-scramble); this mutant was found not to fold by
15N-edited HSQC analysis (data not shown), demonstrating an interac-
tion of Crk1 with only the folded SH3 domain.
We next wanted to determine whether Crk1 interacts with both the
PKTPAK motif and SH3 domain. Kal5, an isoform that includes the
PKTPAK motif but not the SH3 domain, was purified from transfected
HEK-293 cells. The purified protein was incubated with GST or GST-
Crk1, and binding was assessed byWestern blotting. Myc-Kal5 showed
robust binding to GST-Crk1, but not to GST, demonstrating a direct
FIGURE6.Crk-SH3binds to theSH3domainand
PKTPAK motif of Kalirin and inhibits its GEF
activity. A, shown are the results from Western
analysis of Kal8 binding to SH3 domains. Cell
extracts prepared from HEK-293 cells expressing
Kal8 were incubatedwith an array containing GST
or various GST-SH3 fusion proteins (80 ng (L) and
400 ng (H)). The key identifies the position of each
SH3 domain protein. PI3, phosphoinositide 3-ki-
nase regulatory subunit. B, a GST pulldown exper-
imentwasperformed to assess bindingof purified
Crk1 (12 ng) to different GST-Kalirin fusion pro-
teins (2 g). The Input sample represents 20% of
the sample subjected to GST pulldown analysis. A
Coomassie Blue-stained gel of the GST fusion pro-
teins is shown. SH3RT-scramble refers to a mutant
SH3 domain protein containing a scrambled RT-
Src loop (1654HSSE1657 to 1654SHES1657). K7-C-ter-
minus, Kal7 C terminus. C, purified Myc-Kal5 (0.1
g) binding to GST or GST-Crk1 (5 g) was
assessed in a GST pulldown experiment. The PKTP
peptide (0.5 mM) was added as indicated. A West-
ernblot (WB)withanti-MycantibodyandaCoomas-
sie Blue-stained gel are shown. D, lysates prepared
from 293 cells cotransfected with Myc-Kal8 or Myc-
Kal8(PKTA) andwithCrk1 or Crk1(W170K)were ana-
lyzed by co-immunoprecipitation. Myc-Kal8 immu-
noprecipitated (IP) with anti-Myc antibody was
analyzedbyWesternblottingwithanti-Crkandanti-
Myc antibodies. E, a schematic representationof the
regions responsible for the Kalirin/Crk interaction is
shown. F, Crk inhibited the GEF activity of Kal8 in
cells. Lysates fromHEK-293cells transfectedwiththe
vectors indicated were analyzed for Rac2 activation
using theGST-Pak p21-bindingdomain (see “Exper-
imental Procedures”). Cell lysates (1⁄25th of the pull-
downsample)wereanalyzedforexpressionoftrans-
fectedproteins byWestern blottingwith antibodies
toMyc and Crk.
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interaction (Fig. 6C). In the presence of excess PKTP peptide, the inter-
action of Kal5 with GST-Crk1 was significantly reduced, indicating that
the PKTPAK motif in Kalirin binds to the SH3 domain of Crk1.
To determine whether the interaction of Crk-SH3 with the Kalirin
PKTPAKmotif is necessary for the interaction of Crk1 with Kalirin, we
performed co-immunoprecipitationwith variousmutantKal8 andCrk1
proteins. Lysates were prepared from HEK-293 cells transfected with
wild-type Kal8, wild-type Crk1, or Crk1(W170K), which harbors a
mutation that blocks the interaction of its SH3 domain with its PXXP
ligands (43). Both wild-type Crk1 and Crk1(W170K) co-immunopre-
cipitated with Myc-Kal8 (Fig. 6D). Wild-type and mutant Crk1 also
co-immunoprecipitated with Kal8 containing a mutation in its consen-
sus Crk-binding motif (Kal8(PKTA)), but not from control cells trans-
fected with empty vector. Crk also co-immunoprecipitated with Kalirin
from embryonic day 17 mouse brain (data not shown). These experi-
ments indicate the Kalirin PKTPAKmotif is not necessary for the inter-
action of Kalirin with Crk1, whereas Kal-SH3 is necessary for this inter-
action (Fig. 6D).
We next mapped the region of Crk1 bound to Kalirin. Crk1 contains
single SH2 and SH3 domains (Fig. 6E). Chicken Crk1 contains a PXXP
ligand within its SH2 domain (NP_001007847), which could serve as a
ligand for Kal-SH3. However, purified Kal8 binding to GST-Crk1-SH2
was similar to background binding observed with GST, indicating that
neither Crk1-SH2 nor its PXXP motifs are involved in binding Kalirin
(data not shown).
GST-Crk1-SH3 interacted with Kal8 in the SH3 array experiment
(Fig. 6A), and the SH3 domain of Kalirin was necessary for this interac-
tion. These results unexpectedly indicate that Kal-SH3 binds to Crk1-
SH3. Together, the results of these mapping experiments indicate that
Crk1-SH3 forms a bidentate interaction with both the Kalirin PKTPAK
motif and Kal-SH3 (Fig. 6E).
Crk Negatively Regulates the GEF Activity of Kalirin—Because the
SH3 domain/PKTP region of Kalirin regulates its GEF activity and
because Crk binds this region, we suspected that Crk would affect Kali-
rin GEF activity. To test this hypothesis, the levels of activated Rac in
cells were measured using an effector-based assay (41, 45, 56). Reverse
transcription-PCR analysis of HEK-293 cells identified Rac2, not Rac1
or Rac3; human Rac1 has 92% amino acid identity to Rac2. Kinetic
analysis of Kal-GEF1 in fluorogenic exchange assays showed that, like
Rac1, Rac2 is a good substrate (kcat 30 0.4 h	1 and Km 2.6 0.5
M) (41) (data not shown). Therefore, the p21-binding domain of Pak
was used to compare the levels of activated Rac2 in HEK-293 cells
expressing Kal8, Crk1, or both proteins (Fig. 6F ). Expression of Kal8
produced significant activation of Rac2, whereas expression of Crk1 did
not (Fig. 6F ). Coexpression of Crk1 completely eliminated the ability of
Kal8 to activate Rac2 (Fig. 6F ). The activity assays, together with the
GST binding and co-immunoprecipitation experiments, showed that
the interaction of Crk with Kalirin nearly completely eliminated GEF
activity. Therefore, the intermolecular interaction of Crk1 with the Kal-
SH3/linker region potently inhibits its GEF activity; in contrast,
intramolecular interactions in this region ofKalirinmay bemore impor-
tant for fine-tuning GEF activity.
DISCUSSION
Structure of Kal-SH3—The three-dimensional fold of Kal-SH3 is sim-
ilar to that of other SH3domains, as exemplified by comparisonwith the
Sem5 SH3 domain structure (Fig. 2E). The major differences in the
backbone overlay are in the n-Src and distal Src loops, which are longer
in Kalirin. The divergence of the Kalirin n-Src loop from the structures
of other SH3 domains is interesting because residues in this loop are
involved in a novel PXXP ligand-binding site(s). Although a cis-Pro in
the distal loop does not directly contribute to this binding site(s), it
provides a potentially attractive means of regulating ligand binding
through cis,trans-isomerization. Similarly, in the RhoGEF protein Vav,
an Ile–cis-Pro bond in its N-terminal SH3 domain positions the RT-Src
loop in an orientation that blocks the canonical PXXP-binding site,
whereas the trans-Pro form does not (38).
Cooperative Binding of PXXP Ligands to Novel Site(s) on Kal-SH3—
We originally hypothesized that Kal-SH3 would bind through either an
intra- or intermolecular interaction with PXXP ligands at the canonical
PXXP-binding site observed in many other SH3 structures. We were
surprised that the three different internal PXXPmotifs tested interacted
instead with a novel site(s), with the PKTP ligand showing cooperative
binding.
Lack of binding to the canonical SH3 domain ligand-binding sitemay
be due to the limited number of PXXP peptides tested and failure to
identify the correct in vivo ligand; however, we favor the hypothesis that
Kal-SH3 has unique site(s) for binding PXXP peptides. Several hydro-
phobic residues that form the hydrophobic pockets in other SH3
domains that accommodate the Pro residues in the PXXP polyproline
type II helix are not conserved in Kalirin (Fig. 4B) (57). Based on known
SH3 domain structures, Gln24 in Kalirin should be Phe or Trp; in addi-
tion, several hydrophobic residues expected in the 310 helix are absent
from Kalirin.
Trp54 is a canonical PXXP ligand-binding residue that is conserved in
nearly all SH3 domains; mutation of this residue generally blocks ligand
interaction (14, 58, 59). Consistent with our identification of a different
binding site(s), the corresponding Trp residue is not conserved in all
Kalirin homologs. Mutation of this conserved Trp residue in the Trio
N-terminal SH3 domain disrupts neurite outgrowth (14); however,
based on our analysis of a Kal-SH3 mutant containing a scrambled RT-
Src loop, this mutation may disrupt folding of the SH3 domain. Search-
ing2400 SH3 domain sequences in the SMARTDatabase has revealed
several other SH3 domains that lack this Trp residue (A57152,
XP_044334, KIAA0318, NP_058589, Q62270, NP_498918, NP_004758,
and NP_508660), suggesting that these SH3 domains interact with pro-
line-rich ligands at an alternative site, as Kalirin does. Consistent with
this hypothesis, mutation of the corresponding Trp residue in PSD-95
does not block an intramolecular SH3 domain/ligand interaction (16).
Titration of Kal-SH3 with the PKTP peptide yielded a cooperative
binding isotherm for all residues showing chemical shift changes and a
Hill coefficient of 2, suggesting multiple binding sites for the PKTP
ligand. Few cooperative binding isotherms have been observed in chem-
ical shift titration experiments. Analysis of the PXXP ligand binding to
the Sem5 SH3 domain showed that residues in the RT-Src loop do not
contact ligand, but have significant cooperative changes in chemical
shifts (60). Similar large changes in chemical shifts of residues in the
RT-Src loop of Kal-SH3 are observed upon binding of PXXP peptides.
Because the PLSP peptide (which does not bind to the RT-Src loop) also
produces these changes in chemical shifts, thismay be an intrinsic coop-
erative communication between sites 1 and 2 in Kal-SH3. Cooperative
binding of three calcium ions to yeast calmodulin has been observed in
chemical shift titration experiments (61). This cooperativity derives
from an interaction of the N- and C-terminal calcium-binding domains
of calmodulin that affects their affinity for calcium. In our study, coop-
erativity suggests that a single SH3 domain contains two PXXP-binding
sites.
Surface mapping of Kal-SH3 residues with ligand-induced chemical
shift changes provided support for the two-site model. The PKTP pep-
tide bound to clusters of residues in sites 1 and 2, whereas the PLSP
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peptide in spectrin repeat 3 affected residues only in site 1. Site 1
involves several residues from the RT-Src and n-Src loops; the n-Src
loop is longer in Kalirin and Trio than inmany other SH3 domains. The
PLPP peptide bound primarily to site 2. Site 2 involves segments of the
1,4, and6 sheets. Although the chemical shift titration experiments
identified two clusters of residues located immediately proximal to each
other, additional residues were affected. Although we cannot rule out
the possibility that there is a single PXXP-binding site, the cooperative
binding isotherms, Hill plots, chemical shift mapping, and evolutionary
conservation of PXXP-binding sites strongly support a two-site model.
It is clear that the PXXP peptides tested did not interact with Kal-SH3
at a canonical PXXP-binding site. Non-canonical SH3 domain ligand-
binding sites have been described in Grb2, Pex13p, Vav, and p67phox
(Fig. 4B, lower) (59, 62–64). Furthermore, the OB-fold is very similar to
the SH3 domain fold and binds oligonucleotides or oligosaccharides
(65). Additional studies will be required to determine whether Kal-SH3
contains one or two PXXP-binding sites and whether the PXXP ligands
bind Kal-SH3 by adopting a polyproline type II helix structure. The
AKTP and tPKTA peptides, which each lack one key Pro residue, bind
with 30-fold lower affinity, indicating that both prolines are important
for binding.
It is possible that peptide binding to Kal-SH3 does not mimic an
intermolecular interaction in full-length Kalirin. However, we have
compared 15N-edited HSQC spectra of Kal-SH3 and Kal-SH3 with sat-
urating PKTP peptide with a spectrum of the PH-linker-SH3 domain
fragment (data not shown). This spectrum shows resonances that are
consistent with the PKTP sequence being bound to the SH3 domain.
Therefore, this experiment supported the presence of an intramolecular
SH3 domain/PKTP interaction in full-length Kalirin.
The SH3 Domain of Kalirin Inhibits Its GEF Activity through an
Intramolecular Interaction—Kal-SH3 bound toKal-GEF1 and inhibited
its GEF activity only when in the presence of a PXXP peptide (Fig. 5, A
and C), suggesting that the SH3 domain/peptide interaction mediates
binding toKal-GEF1.All three PXXPmotifs inKal8 can bind toKal-SH3
individually or in two possible configurations (based on surface map-
ping experiments; see model in Fig. 7). Although mutation of any indi-
vidual PXXPmotif did not affect theGEF activity of Kal8,mutation of all
three PXXP motifs (Kal8PXXP) resulted in a modest 1.5-fold increase
in GEF activity. When a single PXXP is mutated, one or two of the
remaining PXXP motifs can presumably bind Kal-SH3 and inhibit its
GEF activity. In summary, we think that Kal8PXXP has more activity
that Kal8 because it does not allow binding of the SH3 domain to any of
the PXXP ligands and thus blocks interaction of the SH3 domain-PXXP
complex with the proximal GEF1 domain. Binding of the SH3 domain-
PXXP complex to GEF1 may sterically reduce the accessibility of Kal-
GEF1 to its substrate.
The relatively weak intramolecular SH3 domain/PXXP interactions
provide an attractivemode ofmodulation. Disruption of intramolecular
SH3 domain/PXXP interactions would enhance GEF activity and gen-
erate two new binding sites (Kal-SH3 and PXXP) for intermolecular
interactions. This mode of regulation is known for Itk, a kinase that is
activated when Grb2 or Sam68 binds to both its SH3 domain and PXXP
motif (17). In support of our findings of SH3 domain regulation of Rho-
GEFs, an intramolecular SH3 domain-mediated regulation of Ost was
suggested previously based on the transformation activity of several
splice variants of rat Ost (human ortholog called Dbs) (13).
Severalmechanismsmay be needed to fine-tune levels of GEF activity
and to control their potent effects on cells. Like Kalirin, many RhoGEFs
have SH3 domains preceding or following their GEF domains (Fig. 1).
Eight of these 22 human RhoGEFs also contain putative intramolecular
PXXP ligands between their GEF and SH3 domains. Because some SH3
domains recognize non-canonical ligands, intramolecular SH3 domain-
ligand complexesmay be relevant to the regulation of other RhoGEFs as
well (59, 63, 64, 66). For example, one of the five SH3 domains in inter-
FIGURE 7.Model of how intramolecular SH3 domain/ligand interactions and intermolecular Kalirin/Crk binding affect GEF activity. Although our data strongly support two
PXXP-binding sites in Kal-SH3, as depicted in thismodel (with site 1 colored blue and site 2 colored green), we cannot rule out a single PXXP-binding site. The PKTP ligand is indicated
by light blue ovals, and thePLPP ligandbygreen ovals. Crk is colored red. The PLSP ligand is located in spectrin repeat 3 (colored cyan). The Sec14pdomain and twoN-terminal spectrin
repeats in Kal8 are not shown.
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sectin associates with a non-canonical SH3 domain ligand in its Dbl
homology domain, resulting in inhibition of Cdc42 binding and GEF
activity toward this RhoGTPase (67). Although its effects onGEF activ-
ity have not been investigated, binding of a PXXPmotif in the faciogeni-
tal dysplasia RhoGEF Fgd1 to the cortactin SH3 domain plays a role in
actin assembly (68).
Crk Is a Kalirin-binding Partner That Inhibits GEF Activity—To
identify SH3 domain ligands that might disrupt intramolecular Kal-
SH3/PXXP interactions, we used an SH3 domain array. The screen
identified Crk, which also co-immunoprecipitated and co-localized
with Kalirin. This interaction is consistent with the fact that the N-ter-
minal SH3 domains of Crk and cortactin are the only SH3 domains
known to prefer the binding motif PXXPXK, which is present in Kalirin
(55, 69). Furthermore, the connection between Crk and Kalirin is sup-
ported by the observation that the Crk ortholog in C. elegans (CED-2)
genetically interacts with the Kalirin ortholog (UNC-73) in P-cell
migration (51). Src, Yes, spectrin, Fyb, and Fgrwere also identified in the
SH3 domain screen andmay also have functions associatedwithKalirin.
GST pulldown and co-immunoprecipitation experiments demon-
strated an interaction of Crk1-SH3 with both the PXXPXK motif and
Kal-SH3. Although the observation of Crk1/Kalirin SH3 domain het-
erodimers was surprising, the structures of other SH3 domains have
revealed direct dimeric SH3/SH3 domain contacts (29, 70). Like the
intramolecular Kalirin SH3 domain-PKTPmotif complex, the intermo-
lecular Kal8-Crk complex strongly inhibited GEF activity toward Rac.
Likely explanations for the observed inhibition are that Crk locks the
intramolecular Kal-SH3 PXXP ligand into an inhibitory conformation,
disrupting an internal SH3 domain/PXXP interaction, allosterically
affecting Kalirin GEF activity, or sterically hindering the association of
GEF with Rac (Fig. 7). We do not know what factors or cellular events
relieve Crk-mediated inhibition of Kal8. One intriguing possibility is
that stimulation of TrkA, a neurotrophin receptor, with nerve growth
factor liberates Crk-mediated inhibition of Kalirin. This hypothesis is
supported by the interaction of the Kalirin N-terminal PH domain (part
of the GEF1 domain) with TrkA, enhancement of nerve growth factor-
induced activation of Rac by Kalirin expression, and the important role
of Crk in pathways downstream of TrkA (52, 54, 71, 72). Further exper-
imentation will be required to decipher the complexities of the SH3
domain/ligand interactions that control Kalirin GEF activity.
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